Intestinal Microbiome and Chemotherapy

Nantes University Hospital40 enrolled

Overview

Chemotherapy is commonly used as myeloablative conditioning treatment to prepare patients for haematopoietic stem cell transplantation (HSCT). Chemotherapy leads to several side effects, with gastrointestinal (GI) mucositis being one of the most frequent. Current models of GI mucositis pathophysiology are generally silent on the role of the intestinal microbiome. The aim of the study is to identify functional mechanisms by which the intestinal microbiome may play a key role in the pathophysiology of GI mucositis, the investigators applied high throughput DNA-sequencing analysis to identify microbes and microbial functions that are modulated following chemotherapy.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Diarrhea

Interventions

patients stool collectionOTHER

patients stool collection

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Participants with non-Hodgkin's lymphoma * Participants receiving the same myeloablative conditioning regimen for five consecutive days, including high-dose Carmustine (Bis-chloroethylnitrosourea), Etoposide, Aracytine and Melphalan. Exclusion Criteria: * Patients with a history of Inflammatory Bowel Diseases (IBD), exposed to probiotics, prebiotics or broad-spectrum antibiotics, or administered nasal-tube feeding or parenteral nutrition in the month prior to initiation of the study.

Locations (1)

CHU de Nantes

Nantes, France

Outcomes

Primary Outcomes

analyze of the fecal samples using 16S ribosomal ribonucleic acid (rRNA) gene sequencing

Time frame: baseline

analyze of the fecal samples using 16S ribosomal ribonucleic acid (rRNA) gene sequencing

Time frame: at day 7

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.